ScinoPharm Taiwan Ltd (1789) - Total Assets
Based on the latest financial reports, ScinoPharm Taiwan Ltd (1789) holds total assets worth NT$11.86 Billion TWD (≈ $373.58 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ScinoPharm Taiwan Ltd book value and equity for net asset value and shareholders' equity analysis.
ScinoPharm Taiwan Ltd - Total Assets Trend (2007–2025)
This chart illustrates how ScinoPharm Taiwan Ltd's total assets have evolved over time, based on quarterly financial data.
ScinoPharm Taiwan Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
ScinoPharm Taiwan Ltd's total assets of NT$11.86 Billion consist of 46.3% current assets and 53.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 26.2% |
| Accounts Receivable | NT$624.03 Million | 5.3% |
| Inventory | NT$1.64 Billion | 13.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$15.36 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how ScinoPharm Taiwan Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of ScinoPharm Taiwan Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ScinoPharm Taiwan Ltd's current assets represent 46.3% of total assets in 2025, an increase from 38.0% in 2007.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2025, up from 0.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 13.8% of total assets.
ScinoPharm Taiwan Ltd Competitors by Total Assets
Key competitors of ScinoPharm Taiwan Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
ScinoPharm Taiwan Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.74 | 8.61 | 8.26 |
| Quick Ratio | 5.43 | 6.43 | 6.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$4.78 Billion | NT$5.84 Billion | NT$5.37 Billion |
ScinoPharm Taiwan Ltd - Advanced Valuation Insights
This section examines the relationship between ScinoPharm Taiwan Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.59 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | NT$11.86 Billion |
| Market Capitalization | $505.73 Million USD |
Valuation Analysis
Below Book Valuation: The market values ScinoPharm Taiwan Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: ScinoPharm Taiwan Ltd's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ScinoPharm Taiwan Ltd (2007–2025)
The table below shows the annual total assets of ScinoPharm Taiwan Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$11.86 Billion ≈ $373.58 Million |
-0.71% |
| 2024-12-31 | NT$11.94 Billion ≈ $376.26 Million |
+1.89% |
| 2023-12-31 | NT$11.72 Billion ≈ $369.29 Million |
-1.59% |
| 2022-12-31 | NT$11.91 Billion ≈ $375.27 Million |
+1.88% |
| 2021-12-31 | NT$11.69 Billion ≈ $368.34 Million |
-1.31% |
| 2020-12-31 | NT$11.85 Billion ≈ $373.24 Million |
+1.47% |
| 2019-12-31 | NT$11.67 Billion ≈ $367.81 Million |
-7.07% |
| 2018-12-31 | NT$12.56 Billion ≈ $395.81 Million |
-1.09% |
| 2017-12-31 | NT$12.70 Billion ≈ $400.16 Million |
-0.64% |
| 2016-12-31 | NT$12.78 Billion ≈ $402.73 Million |
+4.59% |
| 2015-12-31 | NT$12.22 Billion ≈ $385.05 Million |
+7.47% |
| 2014-12-31 | NT$11.37 Billion ≈ $358.27 Million |
-0.98% |
| 2013-12-31 | NT$11.48 Billion ≈ $361.82 Million |
+11.07% |
| 2012-12-31 | NT$10.34 Billion ≈ $325.76 Million |
+9.07% |
| 2011-12-31 | NT$9.48 Billion ≈ $298.68 Million |
+29.90% |
| 2010-12-31 | NT$7.30 Billion ≈ $229.93 Million |
+25.31% |
| 2009-12-31 | NT$5.82 Billion ≈ $183.49 Million |
+1.08% |
| 2008-12-31 | NT$5.76 Billion ≈ $181.52 Million |
+2.21% |
| 2007-12-31 | NT$5.64 Billion ≈ $177.59 Million |
-- |
About ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract ma… Read more